Molecule

Clindamycin

Also known as clindamycin hydrochloride, clindamycin phosphate

Available on requestAntibiotics Dermatology

Presentations: 37
Brands: 12
Manufacturers: 9
Available from stock: 0

Clindamycin is a lincosamide antibacterial indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. It is available as capsules, injection and gel for oral, topical and intravenous use. MedsAcross supplies Clindamycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class: Lincosamide Antibacterial, Decreased Sebaceous Gland Activity, Neuromuscular Blockade
ATC classification: D10AF01 Clindamycin · Acne treatments, subgroup D10A, subgroup D10AFG01AA10 Clindamycin · Gynaecological anti-infectives, subgroup G01A, subgroup G01AAJ01FF01 Clindamycin · Lincosamides
US FDA first approval: 22 February 1970
EU status: Not recorded
Orphan designation: Not recorded
WHO essential medicine: Not recorded
India (CDSCO): Not yet confirmed against CDSCO approval lists
Routes: Oral, Topical, Intravenous, Intramuscular, Vaginal
Dosage forms: Capsule, Injection, Gel, Topical solution, Lotion, Foam, Vaginal cream, Swab
Identifiers: UNII 3U02EL437CRxCUI 2582CAS 18323-44-9DrugBank DB01190Q422273

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Source: US FDA prescribing information

How it works

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Source: US FDA prescribing information

Dosing overview

If significant diarrhea occurs during therapy, this antibacterial drug should be discontinued. Administer CLEOCIN HCl Capsules with a full glass of water (6 to 8 ounces, approximately 200 to 250 mL) and at least 30 minutes before lying down to reduce the potential for esophageal irritation. Adults: Serious infections – 150 to 300 mg every 6 hours. More severe infections – 300 to 450 mg every 6 hours. Pediatric Patients (who are able to swallow capsules): Serious infections – 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections – 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses. Clindamycin should be dosed based on total body weight regardless of obesity. CLEOCIN HCl Capsules are not suitable for pediatric patients who are unable to swallow them whole.

Source: US FDA prescribing information

Contraindications

CLEOCIN HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Source: US FDA prescribing information

Warnings and precautions

WARNING Clostridioides difficile infection (CDI) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. See BOXED WARNING Clostridioides difficile Infection Clostridioides difficile infection (CDI) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDI.

Source: US FDA prescribing information

Side effects

The following reactions have been reported with the use of clindamycin. Infections and Infestations: Clostridioides difficile colitis Gastrointestinal: Abdominal pain, pseudomembranous colitis, nausea, vomiting, and diarrhea. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. Esophagitis (including necrotizing esophagitis) and esophageal ulcer have been reported, particularly when taken in a lying position or with a small amount of water. An unpleasant or metallic taste has been reported after oral administration. Hypersensitivity Reactions: Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy.

Source: US FDA prescribing information

Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness. In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.

Source: US FDA prescribing information

Storage

Store at controlled room temperature 20° to 25° C (68° to 77° F).

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

37 presentations of Clindamycin, sorted by availability.

Medicine	Manufacturer	Register	Availability
Clindamycin 300 mg capsuleOralGeneric name	—	US FDA	Available on request
Clindamycin 150 mg capsuleOralGeneric name	—	US FDA	Available on request
Clindamycin 1% gelTopicalGeneric name	—	US FDA	Available on request
Clindamycin 10 mg/mL topical solutionTopicalGeneric name	—	US FDA	Available on request
Clindamycin 75 mg capsuleOralGeneric name	—	US FDA	Available on request
Clindamycin 10 mg/mL lotionTopicalGeneric name	—	US FDA	Available on request
Clindamycin 1% foamTopicalGeneric name	—	US FDA	Available on request
Clindamycin 600 mg/50 mL injectionIntravenousGeneric name	—	US FDA	Available on request
Clindamycin 900 mg/50 mL injectionIntravenousGeneric name	—	US FDA	Available on request
Cleocin Phosphate 600 mg/4 mL injectionIntramuscular, intravenous	Pharmacia & Upjohn	US FDA	Available on request
Clindamycin 300 mg/50 mL injectionIntravenousGeneric name	—	US FDA	Available on request
Cleocin Phosphate 300 mg/2 mL injectionIntramuscular, intravenous	Pharmacia & Upjohn	US FDA	Available on request
Clindamycin 600 mg/4 mL injectionIntramuscular, intravenousGeneric name	—	US FDA	Available on request
Clindamycin Phoaphate Topical Solution USP, 1% 10 mg/mL topical solutionTopical	Encube Ethicals	US FDA	Available on request
Cleocin Phosphate 900 mg/6 mL injectionIntramuscular, intravenous	Pharmacia & Upjohn	US FDA	Available on request
Clindamycin 1 g/100 mL gelTopicalGeneric name	—	US FDA	Available on request
Clindamycin 10 mcg/mL lotionTopicalGeneric name	—	US FDA	Available on request
Clindamycin 2% vaginal creamVaginalGeneric name	—	US FDA	Available on request
Clindamycin 300 mg/2 mL injectionIntramuscular, intravenousGeneric name	—	US FDA	Available on request
Clindamycin 900 mg/6 mL injectionIntramuscular, intravenousGeneric name	—	US FDA	Available on request
Clindacin ETZ 10 mg swabTopical	Eurofarma	US FDA	Available on request
Clindacin P 10 mg/mL topical solutionTopical	Eurofarma	US FDA	Available on request
Cleocin 100 mg vaginal suppositoryVaginal	Pharmacia & Upjohn	US FDA	Available on request
Cleocin 2% vaginal creamVaginal	Pharmacia & Upjohn	US FDA	Available on request
Cleocin Hydrochloride 150 mg capsuleOral	Pharmacia & Upjohn	US FDA	Available on request
Cleocin Hydrochloride 300 mg capsuleOral	Pharmacia & Upjohn	US FDA	Available on request
Cleocin Hydrochloride 75 mg capsuleOral	Pharmacia & Upjohn	US FDA	Available on request
Cleocin Phosphate 9000 mg/60 mL injectionIntramuscular, intravenous	Medical Purchasing Solutions	US FDA	Available on request
Cleocin T 10 mg/mL lotionTopical	Pharmacia & Upjohn	US FDA	Available on request
Clindacin 1% foamTopical	Medimetriks Pharmaceuticals	US FDA	Available on request
Clindamycin 1 g/10 mL gelTopicalGeneric name	—	US FDA	Available on request
Clindamycin 11.9 mg/mL topical solutionTopicalGeneric name	—	US FDA	Available on request
Clindamycin 9000 mg/60 mL injectionIntravenousGeneric name	—	US FDA	Available on request
Clindamycin Phoaphate Topical USP, 1% 10 mg/mL topical solutionTopical	A-S Medication Solutions	US FDA	Available on request
Clindesse 2% vaginal creamVaginal	Padagis Israel Pharmaceuticals	US FDA	Available on request
Xaciato 2% vaginal gelVaginal	Organon	US FDA	Available on request
Clindagel 10 mg/mL gelTopical	Bausch Health	US FDA	Available on request

Brands by market

12 brand names across 1 markets.

Brand names by country

United States

Cleocin Cleocin Hydrochloride Cleocin Phosphate Cleocin T Clindacin Clindacin ETZ Clindacin P Clindagel Clindamycin Phoaphate Topical Solution USP, 1%Clindamycin Phoaphate Topical USP, 1%Clindesse Xaciato

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

Register	Status	Source
US FDA	First approved 22 February 1970	Drugs@FDA
EU (EMA)	Not recorded	—
India (CDSCO)	Not yet confirmed against CDSCO approval lists	—
United States	Registered	US FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Clindamycin in public data. This is not a list of approved uses, see the clinical information.

Acne Babesiosis Bacterial vaginosis Bacteroides infectious disease Botulism Campylobacteriosis Cellulitis Dental abscess Erysipelothrix rhusiopathiae infectious disease Lemierre's syndrome Malaria Pneumocystosis Scarlet fever Sinusitis Skin infection Staphylococcal infection Syphilis Tonsillitis Toxoplasmosis

Questions and answers

Is Clindamycin available for export from India?

Yes, on request. MedsAcross lists 37 presentations of Clindamycin and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Clindamycin have?

The catalogue lists 12 brand names for Clindamycin, including Cleocin, Cleocin Hydrochloride, Cleocin Phosphate, Cleocin T, Clindacin, Clindacin ETZ, Clindacin P, Clindagel.

Is Clindamycin approved by the US FDA?

Yes. The US FDA first approved Clindamycin on 22 February 1970, according to Drugs@FDA.

Does Clindamycin need cold chain shipping?

No listed presentation of Clindamycin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Clindamycin in?

Clindamycin is classified under ATC code D10AF01 (Clindamycin).

References

Cleocin Hydrochloride prescribing information (Pharmacia & Upjohn). U.S. National Library of Medicine, DailyMed. Retrieved 16 September 2026

Request Clindamycin for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quote Read the import guides